BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ZARS pharma Announces FDA Approval Of Synera(TM) Topical Local Anesthetic Patch


10/19/2005 5:09:02 PM

SALT LAKE CITY, July 26 /PRNewswire/ -- ZARS, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Synera(TM), a topical local anesthetic patch, developed under the name of S-Caine(TM) Patch (lidocaine 70 mg and tetracaine 70 mg). This is ZARS' first product to be approved by the FDA.

The patch will be used to numb the skin before various medical procedures such as superficial venous access as well as certain dermatological procedures. The product is indicated for use in children and adults and will soon be for sale in the U.S.

Synera has a thin layer of a local anesthetic formulation integrated with an oxygen-activated heating element. The heating element enhances the delivery of the local anesthetics into the skin. When removed from its storage pouch, the patch begins to heat, warming the skin after application.

In clinical trials, the most common side effect was local skin reactions, such as erythema, blanching and edema. Synera should not be used for a longer duration than recommended, and is contraindicated in patients with a known history of sensitivity to lidocaine, tetracaine, or local anesthetics of the amide or ester type.

Larry Rigby, ZARS' CEO, stated, "We are thrilled with the FDA approval. Synera will provide a new option in reducing the pain associated with common procedures, and will, we believe, be an excellent option for use in children. The FDA's approval is also a major milestone for ZARS, showing that our team is capable of developing and getting to market through the NDA process innovative medical products that improve patient care."

ZARS filed an application to market Synera in Europe last April.

Since its founding as a spin-out from the University of Utah in 1997 by Jie Zhang, Ph.D, Michael Ashburn, M.D., MPH, Larry Rigby, and Theodore Stanley, M.D., ZARS has initiated development of proprietary products that deliver drugs into and through the skin, using CHADD (controlled heat assisted drug delivery), phase changing creams, and other technologies. The Company's web site is http://www.zars.com.

Contact: Larry Rigby (CEO) or Robert Lippert (President & COO) ZARS pharma 1142 West 2320 South Salt Lake City, UT 84119 Phone: (801) 350-0202 ldr@zars.com; rlippert@zars.com

ZARS pharma

CONTACT: Larry Rigby, CEO, ldr@zars.com, or Robert Lippert, President &COO, rlippert@zars.com, +1-801-350-0202, both of ZARS pharma



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES